ArticlePharmaceutics2024

Vedolizumab Clearance as a Surrogate Marker for Remission in Inflammatory Bowel Disease Patients: Insights from Real-World Pharmacokinetics.

Srđan Marković et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.